Insurance Expansion Raises Stakes for ImpediMed’s US Commercial Growth

Expanded Insurance Coverage Marks Key Milestone

ImpediMed Limited (ASX, IPD) has announced a significant advance in the commercialisation of its SOZO Digital Health Platform, following a major US health insurer’s decision to recognise bioimpedance spectroscopy (BIS) as medically necessary for lymphedema assessment. This insurer, ranked fifth largest in the US and a Blue Cross Blue Shield licensee across five states, has approved CPT Code 93702, enabling reimbursement for the use of ImpediMed’s technology.

This development dramatically broadens patient access, pushing the total number of covered lives for SOZO’s lymphedema testing to over 301 million, or approximately 86% of the US population. Notably, this includes large states such as Texas and Illinois, which are among the five states covered by the insurer’s plans.

Implications for Breast Cancer Survivors

Lymphedema is a common and often debilitating side effect following breast cancer treatment, characterized by swelling due to lymphatic fluid buildup. Early detection is critical to prevent progression and reduce long-term complications. The expanded insurance coverage means millions more patients can now access timely and accurate monitoring through BIS technology, which is uniquely offered by ImpediMed’s FDA-cleared SOZO platform.

Dr Parmjot Bains, Managing Director of ImpediMed, highlighted the importance of this milestone amid the challenging financial landscape of US healthcare. He noted that recognition by a major insurer not only validates the clinical value of BIS but also enhances the feasibility of integrating SOZO-based lymphedema prevention programs across hospital systems nationwide.

Commercial and Market Outlook

This insurance coverage expansion complements recent positive momentum reported in ImpediMed’s Q4 FY25 results and is expected to accelerate commercial uptake. With over 301 million lives covered, including states with large populations, ImpediMed is well-positioned to capitalize on the growing demand for proactive cancer survivorship care.

ImpediMed’s SOZO platform, which also addresses other conditions such as heart failure and malnutrition, benefits from a subscription-based SaaS model that supports recurring revenue growth. The company’s unique position as the sole provider of FDA-cleared BIS technology for lymphedema assessment further strengthens its competitive moat.

While the announcement does not specify immediate revenue impacts or hospital adoption timelines, it signals a clear pathway for broader clinical integration and reimbursement stability, critical factors for sustained growth in the US healthcare market.